PPARδ agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Though many human rights note that Duterte's war on drugs was a stain on his legacy, the anti-narcotics drive received domestic approval during his term, and 58% of the country's barangays were declared by the government cleared of illegal drugs by February 2022.
Humans have more than the commonly cited five senses. The number of senses in various categorizations ranges from 5 to more than 20. In addition to sight, smell, taste, touch, and hearing, which were the senses identified by Aristotle, humans can sense balance and acceleration (equilibrioception), pain (nociception), body and limb position (proprioception or kinesthetic sense), and relative temperature (thermoception). Other senses sometimes identified are the sense of time, echolocation, itching, pressure, hunger, thirst, fullness of the stomach, need to urinate, need to defecate, blood carbon dioxide (CO2) levels, and electric field sensation. All different tastes can be detected on all parts of the tongue by taste buds, with slightly increased sensitivities in different locations depending on the person; the tongue map showing the contrary is fallacious. There are not four primary tastes, but five: in addition to bitter, sour, salty, and sweet, humans have taste receptors for umami, which is a "savory" or "meaty" taste. Fat does interact with specific receptors in taste bud cells, but whether it is a sixth primary taste remains inconclusive. The human sense of smell is not weak or underdeveloped. Humans have similar senses of smell to other mammals, and are more sensitive to some odors than rodents and dogs.
The early 1990s saw a number of successful major product launches, including spicy "Hot Wings" (launched in 1990), popcorn chicken (1992) and, internationally, the "Zinger", a spicy chicken fillet sandwich (1993). By 1994 KFC had 5,149 outlets in the US and 9,407 overall, with over 100,000 employees. In August 1997, PepsiCo spun off its restaurants division as a public company valued at US$4.5 billion (around US$7.3 billion in 2020). The new company was named Tricon Global Restaurants and, at the time, had 30,000 outlets and annual sales of US$10 billion (around US$16 billion in 2020), making it second in the world only to McDonald's. Tricon was renamed Yum! Brands in May 2002.
Sources: en.wikipedia.org
Very soon the scientific papers will be agog with a new discovery which has been added to the many brilliant triumphs of Gower Street. Dr. Otto Hahn, who is working at University College, has discovered a new radioactive element, extracted from a mineral from Ceylon, named Thorianite, and possibly, it is conjectured, the substance which renders thorium radioactive. Its activity is at least 250,000 times as great as that of thorium, weight for weight. It gives off a gas (generally called an emanation), identical with the radioactive emanation from thorium. Another theory of deep interest is that it is the possible source of a radioactive element possibly stronger in radioactivity than radium itself, and capable of producing all the curious effects which are known of radium up to the present. – The discoverer read a paper on the subject to the Royal Society last week, and this should rank, when published, among the most original of recent contributions to scientific literature.
=== External factors === Externally, anything from the weather outside to the age of the performer can affect flexibility. General tissues and collagen change with age influencing the individual.As one ages, performing activities of daily living without pain becomes much harder. By stretching often, one can maintain a level of musculoskeletal fitness that will keep them feeling well. Performers should be aware of over-stretching. Even basic things such as clothing and equipment can affect a performance. Dance surfaces and lack of proper shoes can also affect a performer's ability to perform at their best.
The one-vial formulation is administered as an aqueous intravenous solution that contains the same drug substance in the same concentration as the already approved two-vial formulation. The same grade, quality, and quantity of polysorbate 80 are present in the infusion solution of both formulations. The only difference between these two formulations is the quantity of ethanol.
Smith Eugene Kashper (1992), owner of Pabst Brewing Company Rob Speyer (1992), president of Tishman Speyer, son of billionaire Jerry Speyer '62 Thad Sheely (1993), former COO of Atlanta Hawks Shawn Landres (1994), social entrepreneur, co-founder of Jewish philanthropic organization Jumpstart Welly Yang (1994), real estate developer; former actor and playwright Ann Kim (1995), James Beard Foundation Award-winning restaurateur in Minneapolis Matt Pincus (1995), founder of Songs Music Publishing, son of Warburg Pincus co-founder Lionel Pincus Arnold Kim (1996), founder of MacRumors Daniel M. Ziff (1996), third youngest billionaire hedge fund manager in the U.S., son of publishing magnate William Bernard Ziff Jr. Li Lu (1996), former student leader of the Tiananmen Square protests of 1989, investment banker, founder of Himalaya Capital Michelle Patron (1996), director of sustainability at Microsoft Scott Sartiano (1997), restaurateur Roo Rogers (1998), entrepreneur, business designer, writer, son of British architect Richard Rogers Amol Sarva (1998), founder of Knotel, Peek, and Virgin Mobile USA Amanda Steinberg (1999), wealth advisor and founder of DailyWorth Shazi Visram (1999), founder of Happy Family Peter Kujawski (2000), chairman of Focus Features Robert Reffkin (2000), co-founder and CEO of Compass, Inc.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.